Clinical Trials
3 trialsNCT00706992 2015-10-28
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00005841 2014-05-22
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
University of Southern California
Phase 1 Terminated
NCT00303836 2013-06-06
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Terminated